Literature DB >> 12127304

Diethylnitrosamine induces long-lasting re-expression of insulin-like growth factor II during early stages of liver carcinogenesis in mice.

Harald Lahm1, Katinka Gittner, Ottheinz Krebs, Lisa Sprague, Erhard Deml, Doris Oesterle, Andreas Hoeflich, Rüdiger Wanke, Eckhard Wolf.   

Abstract

The expression of the insulin-like growth factor II (IGF-II) gene (Igf2) in rodents is completely abrogated in almost all adult tissues. A prominent exception are neoplasms in which IGF-II frequently serves as an autocrine growth factor. We have investigated the potential role of Igf2 expression during liver carcinogenesis. After application of diethylnitrosamine (DEN) preneoplastic foci and adenomas emerged in liver tissue of wild-type and phosphoenolpyruvate carboxykinase (PEPCK)-IGF-II transgenic mice. Surprisingly, number and size of preneoplastic foci were not significantly increased in PEPCK-IGF-II mice as compared with wild-type animals. In situ preparation showed that early adenomas expressed Igf2 transcripts. Reverse transcriptase polymerase chain reaction (RT-PCR) and restriction enzyme analysis confirmed that DEN treatment had indeed reactivated the hepatic expression of murine Igf2 in control mice in a dose-dependent manner. This re-expression of Igf2 persisted for at least 18 months. Species-specific RT-PCR analyses also revealed the presence of murine Igf2 mRNAs in some PEPCK-IGF-II mice. A similar reactivation of Igf2 was detected in bovine growth hormone transgenic mice which develop hepatocellular neoplasms with high frequency. Our results suggest that reactivation of Igf2 is an early event during hepatocarcinogenesis in mice. Its appearance in two independent animal models suggests that Igf2 may be important at pivotal checkpoints of hepatocarcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12127304     DOI: 10.1054/ghir.2002.0261

Source DB:  PubMed          Journal:  Growth Horm IGF Res        ISSN: 1096-6374            Impact factor:   2.372


  8 in total

1.  Transcriptional activation of the IGF-II/IGF-1R axis and inhibition of IGFBP-3 by miR-155 in hepatocellular carcinoma.

Authors:  Hend M El Tayebi; Amr A Waly; Reem A Assal; Karim A Hosny; Gamal Esmat; Ahmed I Abdelaziz
Journal:  Oncol Lett       Date:  2015-09-18       Impact factor: 2.967

Review 2.  Functional consequences of IGFBP excess-lessons from transgenic mice.

Authors:  Eckhard Wolf; Marlon R Schneider; Rui Zhou; Thomas M Fisch; Nadja Herbach; Maik Dahlhoff; Rüdiger Wanke; Andreas Hoeflich
Journal:  Pediatr Nephrol       Date:  2004-12-16       Impact factor: 3.714

Review 3.  Could metabolic syndrome lead to hepatocarcinoma via non-alcoholic fatty liver disease?

Authors:  Antonella Scalera; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2014-07-28       Impact factor: 5.742

Review 4.  A review of the molecular mechanisms of chemically induced neoplasia in rat and mouse models in National Toxicology Program bioassays and their relevance to human cancer.

Authors:  Mark J Hoenerhoff; Hue Hua Hong; Tai-vu Ton; Stephanie A Lahousse; Robert C Sills
Journal:  Toxicol Pathol       Date:  2009-12       Impact factor: 1.902

Review 5.  Targeting insulin-like growth factor axis in hepatocellular carcinoma.

Authors:  Jennifer Wu; Andrew X Zhu
Journal:  J Hematol Oncol       Date:  2011-07-05       Impact factor: 17.388

6.  IGF-II transgenic mice display increased aberrant colon crypt multiplicity and tumor volume after 1,2-dimethylhydrazine treatment.

Authors:  Daniela Diehl; Doris Oesterle; Martin W Elmlinger; Andreas Hoeflich; Eckhard Wolf; Harald Lahm
Journal:  J Carcinog       Date:  2006-11-21

Review 7.  Insulin-Like Growth Factor (IGF) System in Liver Diseases.

Authors:  Agnieszka Adamek; Aldona Kasprzak
Journal:  Int J Mol Sci       Date:  2018-04-27       Impact factor: 5.923

8.  Methylation in MIRLET7A3 Gene Induces the Expression of IGF-II and Its mRNA Binding Proteins IGF2BP-2 and 3 in Hepatocellular Carcinoma.

Authors:  Amr A Waly; Nada El-Ekiaby; Reem A Assal; Mohamed M Abdelrahman; Karim A Hosny; Hend M El Tayebi; Gamal Esmat; Kai Breuhahn; Ahmed I Abdelaziz
Journal:  Front Physiol       Date:  2019-01-24       Impact factor: 4.566

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.